In AML resistant to cytarabine and ribavirin, GLI1 was identified as a driver of UDP glucuronosyltransferase (UGT1A) that modified ribavirin and cytarabine through glucuronidation and diminished their efficacy, leading to drug resistance. The gene discussed is GLI1; the disease is acute myeloid leukemia.